BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 22009588)

  • 1. RNA interference and cancer therapy.
    Wang Z; Rao DD; Senzer N; Nemunaitis J
    Pharm Res; 2011 Dec; 28(12):2983-95. PubMed ID: 22009588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNAi in clinical studies.
    Kubowicz P; Żelaszczyk D; Pękala E
    Curr Med Chem; 2013; 20(14):1801-16. PubMed ID: 23432579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. siRNA and miRNA for the treatment of cancer.
    Jankovic R; Radulovic S; Brankovic-Magic M
    J BUON; 2009 Sep; 14 Suppl 1():S43-9. PubMed ID: 19785069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA interference (RNAi)-based plasmonic nanomaterials for cancer diagnosis and therapy.
    Yoon J; Shin M; Lee JY; Lee SN; Choi JH; Choi JW
    J Control Release; 2022 Feb; 342():228-240. PubMed ID: 35016917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases.
    Germain ND; Chung WK; Sarmiere PD
    Mol Aspects Med; 2023 Jun; 91():101148. PubMed ID: 36257857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression.
    He S; Zhang D; Cheng F; Gong F; Guo Y
    Mol Biol Rep; 2009 Nov; 36(8):2153-63. PubMed ID: 19117119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on RNA interference-mediated gene silencing in cancer therapy.
    Ren YJ; Zhang Y
    Expert Opin Biol Ther; 2014 Nov; 14(11):1581-92. PubMed ID: 25010067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for the potential of RNA interference in the treatment of autoimmune diseases: Small interfering RNAs in the spotlight.
    Gorabi AM; Kiaie N; Aslani S; Jamialahmadi T; Johnston TP; Sahebkar A
    J Autoimmun; 2020 Nov; 114():102529. PubMed ID: 32782117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noncoding RNA for Cancer Gene Therapy.
    Zhong X; Zhang D; Xiong M; Zhang L
    Recent Results Cancer Res; 2016; 209():51-60. PubMed ID: 28101687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.
    Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T
    Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dicey role of Dicer: implications for RNAi therapy.
    Merritt WM; Bar-Eli M; Sood AK
    Cancer Res; 2010 Apr; 70(7):2571-4. PubMed ID: 20179193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.
    Singh S; Narang AS; Mahato RI
    Pharm Res; 2011 Dec; 28(12):2996-3015. PubMed ID: 22033880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic delivery of small RNA using lipid nanoparticles.
    Asai T; Oku N
    Biol Pharm Bull; 2014; 37(2):201-5. PubMed ID: 24492716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs and cancer therapeutics.
    Yeung ML; Jeang KT
    Pharm Res; 2011 Dec; 28(12):3043-9. PubMed ID: 21773853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNAi-based drug discovery and its application to therapeutics.
    Hokaiwado N; Takeshita F; Banas A; Ochiya T
    IDrugs; 2008 Apr; 11(4):274-8. PubMed ID: 18379962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo delivery aspects of miRNA, shRNA and siRNA.
    Khatri N; Rathi M; Baradia D; Trehan S; Misra A
    Crit Rev Ther Drug Carrier Syst; 2012; 29(6):487-527. PubMed ID: 23176057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of shRNA and miRNA for Delivery to the CNS.
    Toro Cabrera G; Mueller C
    Methods Mol Biol; 2016; 1382():67-80. PubMed ID: 26611579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry.
    Wang P; Zhou Y; Richards AM
    Theranostics; 2021; 11(18):8771-8796. PubMed ID: 34522211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of RNA interference against cancer.
    Takeshita F; Ochiya T
    Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.